Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06889493 | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | recruiting | Phase 1 | 36 | Peter Hosein, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | recruiting | Phase 1 | 100 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 |
| Apr 28, 2026 |
| clinicaltrials |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06736418 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | active not recruiting | Phase 1 | 17 | Abdera Therapeutics Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550842 | A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 33 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04349436 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies(ARTACUS) | active not recruiting | Phase 1 / Phase 2 | 69 | Replimune, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT04375267 | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours(LuPARP) | completed | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05249114 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | active not recruiting | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05595460 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | active not recruiting | Phase 1 | 21 | RayzeBio, Inc.INDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04560972 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | active not recruiting | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | recruiting | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04261855 | Targeted Therapy and Avelumab in Merkel Cell Carcinoma(GoTHAM) | active not recruiting | Phase 1 / Phase 2 | 19 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05680922 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 41 | Legend Biotech USA IncINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02402920 | Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer | completed | Phase 1 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07456878 | Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03879694 | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 1 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07107490 | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | recruiting | Phase 1 | 122 | Chugai PharmaceuticalINDUSTRY | 3 | Feb 6, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | terminated | Phase 1 / Phase 2 | 2 | Ariceum Therapeutics GmbHINDUSTRY | 2 | Feb 5, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05556473 | F-Tryptophan PET/CT in Human Cancers | recruiting | Phase 1 | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2026source: clinicaltrials